Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival

Mora, Bárbara; Reyes, María; Lobos, Lorena; Del Campo, Matías; Buchegger, Kurt; Zanella, Louise; Riquelme, Ismael; Ili, Carmen; Brebi, Priscilla

Publication:
Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival

Files

Maraviroc cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival.pdf (3.12 MB)

Date

2025

Type:

Article

Collections

Artículos Medicina y Ciencias de la Salud

Descargas totales

0

Vistas totales

1

Métricas

Gestores bibliográficos

Authors

item.page.doiurl

https://doi.org/10.1186/s40659-024-00581-3

URI

https://hdl.handle.net/11447/10999

item.page.accessRights

Acceso Abierto

Abstract

Background: Gastric cancer (GC) is a significant cancer-related cause of death worldwide. GC's most used chemotherapeutic regimen is based on platinum drugs such as cisplatin (CDDP). However, CDDP che...

Citation

Mora-Lagos B, Reyes ME, Lobos-Gonzalez L, Del Campo M, Buchegger K, Zanella L, Riquelme I, Ili CG, Brebi P. Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival. Biol Res. 2025 Jan 18;58(1):4. doi: 10.1186/s40659-024-00581-3

Keywords

C-C chemokine receptor type 5 (CCR5) , C-C motif chemokine ligand 5 (CCL5) , Chemoresistance , Cisplatin (CDDP) , Gastric cancer (GC) , Maraviroc (MVC)

Estadísticas de uso

1 0,8 0,5 0,3 0